Compare Kohl's Corporation (KSS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Kohl's Corporation trades at $20.35 (market cap $2.28B), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 33.4× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.49%). Which is the better fit depends on your goals — on Pluang, investors hold Kohl's Corporation for 48 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| KSS | REGN | |
|---|---|---|
Market Cap | $2.28B | $76.14B |
Volume | 4,960,280 | 500,239 |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $852.03 |
52-Week Low | $11.72 | $557.73 |
Typical Hold Time | 48 Days | 107 Days |
Enterprise Value | $7.88B | $70.85B |
Dividend Yield | 2.49% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $20.10, down 0.1% with a bullish technical signal despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, though revenue has declined from $19.4B in 2022 to $16.2B in 2025. Recent Q2 2026 earnings beat expectations with $1.28 EPS versus $0.58 expected, and the company appointed a new Chief Merchandising Officer in August 2026.
KSS presents a value opportunity with low valuations and improving operational metrics, but faces headwinds from 18 consecutive quarters of declining sales. Analyst consensus is mixed with 30% buy ratings and a $15.50 price target below current levels. The key risk remains consumer spending pressures affecting the retail sector recovery.
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% on the day, with a bearish technical signal from moving averages. The company maintains strong fundamentals, including a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant immunology alliance expansion with Sanofi, valued up to $8 billion, which could drive future growth. Cash flow improved in 2025, with net cash flow turning positive at $634.70 million.
The outlook is positive, supported by robust profitability and strategic collaborations, but faces risks from competition in key drug markets and reliance on pipeline success. Analysts are bullish with a consensus price target of $849.84, implying potential upside. Investors should weigh strong financials against execution risks in drug development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
